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Myocardial dysfunction after ischemia-reperfusioncontinues to be an important problem in cardiac
surgery.1 Evidence implicates inflammatory cytokines,
particularly tumor necrosis factor α (TNF-α), in the
myocardial dysfunction observed after ischemia-reper-
fusion injury.2 TNF-α induces myocardial depression
through multiple mechanisms including disruption of
calcium homeostasis and induction of secondary
depressants such as interleukin 1.1 The alteration in cal-
cium release and response depletes adenosine triphos-
phate (ATP) stores and depresses myocardial contrac-
tile efficiency, resulting in systolic and diastolic
Objective: Inflammatory cytokines, particularly tumor necrosis factor,
contribute to myocardial dysfunction after ischemia-reperfusion injury.
Aprotinin may improve outcomes in cardiac surgery through suppres-
sion of inflammatory mediators. We hypothesized that aprotinin may
exert its beneficial effects through suppression of tumor necrosis fac-
tor α. Methods: Adult rat hearts were precision cut into slices with a
thickness of 200 µm and stored in crystalloid cardioplegic solution alone
or with one of the following additions: aprotinin or tumor necrosis fac-
tor α, aprotinin plus tumor necrosis factor α, a monoclonal antibody to
tumor necrosis factor α, or a polyclonal antibody to the tumor necrosis
factor α receptor. Myocardial biochemical function was assessed by
adenosine triphosphate content and capacity for protein synthesis
immediately after slicing (0 hours) and after 2, 4, and 6 hours of storage
at 4°C. The content of tumor necrosis factor α was measured by an
enzyme-linked immunosorbent assay. Six slices were assayed at each
time point for each solution. The data were analyzed by analysis of vari-
ance and are expressed as the mean ± standard deviation. Results: When
stored in cardioplegic solution containing aprotinin, the heart slices
demonstrated (1) an increase in adenosine triphosphate content and
protein synthesis (P < .0001), (2) a decrease in intramyocardial genera-
tion of tumor necrosis factor α (P ≤ .0311), and (3) a decrease in uptake
of tumor necrosis factor α into the myocardium (P ≤ .002) compared
with storage in cardioplegic solution alone. The presence of an antibody
to tumor necrosis factor α or an antibody to the tumor necrosis factor α
receptor in cardioplegic solution increased intramyocardial adenosine
triphosphate content and protein synthesis (P < .0001). Conclusions:
Aprotinin preserves myocardial biochemical function during cold stor-
age. This preservation of biochemical function is mediated through sup-
pression of the release, uptake, and activity of tumor necrosis factor α.
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CARDIOPULMONARY SUPPORT AND PHYSIOLOGY
APROTININ PRESERVES MYOCARDIAL BIOCHEMICAL FUNCTION DURING COLD STORAGE
THROUGH SUPPRESSION OF TUMOR NECROSIS FACTOR
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dysfunction.1 The mechanisms of TNF-α–induced
myocardial depression can be divided into nitric
oxide–dependent and nitric oxide–independent path-
ways.1 The nitric oxide–dependent pathway medi-
ates TNF-α–induced myofilament desensitization to
calcium.1
In contradistinction, aprotinin may improve out-
comes in cardiac surgery through suppression of
inflammatory mediators.3 Aprotinin has protective
effects on the myocardium after ischemia and reperfu-
sion: improved contractility, faster decline of ischemic
contracture, and preservation of adenine nucleotide
stores.4 Clinically, aprotinin reduces TNF-α blood lev-
els in patients undergoing coronary artery bypass graft-
ing with cardiopulmonary bypass.5 Mechanistically,
aprotinin can inhibit cytokine-induced nitric oxide syn-
thase expression, reducing subsequent nitric oxide pro-
duction by bronchial epithelial cells.6
Linking these two lines of investigation, we hypothe-
sized that aprotinin mediates preservation of myocar-
dial biochemical function through inhibition of the
release, uptake, or activity of TNF-α. To test this
hypothesis, we specifically investigated whether: (1)
aprotinin can preserve myocardial biochemical func-
tion during ischemic cold storage; (2) the myocardium
releases TNF-α during cold storage, before reperfu-
sion; (3) the release of TNF-α is associated with a
decrease in myocardial biochemical function during
cold storage; (4) aprotinin preserves myocardial bio-
chemical function during cold storage by suppression
of the release, uptake, or activity of TNF-α; and (5)
aprotinin suppresses TNF-α–induced nitric oxide pro-
duction within the myocardium.
Materials and methods
Materials. The crystalloid cardioplegic solution used for
all experiments was D5 0.2%NS plus 20 mEq KCl (Baxter,
Deerfield, Ill) to which 10 mEq HCO3– was added. Aprotinin
was obtained from Bayer (West Haven, Conn) and used at a
concentration of 200 KIU/mL with NaOH added to adjust the
pH to 5.5 in all experiments. TNF-α was obtained from R&D
Systems (Minneapolis, Minn) and used at a concentration of
100 pg/mL in all experiments. The monoclonal antibody to
TNF-α (anti–TNF-α antibody) was obtained from R&D
Systems and used at a concentration of 100 pg/mL in all
experiments. TNF-α receptor blockade was accomplished
with a polyclonal antibody to the TNF-α receptor (anti–TNF-
α receptor antibody) obtained from Santa Cruz Biochemical
(Santa Cruz, Calif) and used at a concentration of 100 pg/mL
in all experiments.
Animals. All animals received humane care in compliance
with the guidelines of the Institutional Animal Care and Use
Committee at the University of Utah and the “Guide for the
Care and Use of Laboratory Animals” (NIH Publication 85-
23, revised 1985).
Sprague-Dawley rats (Sasco, Wilmington, Mass) weighing
200-250 g were anesthetized with halothane. With the use of
strict sterile technique, a median sternotomy incision and
cardiectomy of the whole rat heart were rapidly performed.
Slice preparation and storage. Immediately after cardiec-
tomy, the whole rat hearts were placed into 1 of 6 storage
solutions: crystalloid cardioplegic solution alone or crystal-
loid cardioplegic solution with one of the following addi-
tions: aprotinin, TNF-α, aprotinin plus TNF-α, an anti–TNF-
α antibody, or an anti–TNF-α receptor antibody. The whole
rat hearts were then precision cut into slices with a thickness
of 200 µm in the same solution used for storage. Slicing was
performed with a Vitron tissue slicer (Vitron, Tucson, Ariz).
The time from cardiectomy to completion of slicing was 10
minutes. This time interval was strictly controlled and did not
vary between experiments. Ten minutes represents the mini-
mum time from cardiectomy to generation of a set of slices.
Each rat heart was used to generate 4 slices on which bio-
chemical assays were performed immediately after slicing (0
hours) or after 2, 4, and 6 hours of storage at 4°C. Each
myocardial slice was stored in a cold room at 4°C for 2, 4, or
6 hours in a separate 100-mL flask containing 50 mL of solu-
tion. The flasks were gently shaken on an orbital shaker dur-
ing storage. The experiments were repeated 5 times on sepa-
rate occasions for each solution. Slices from 6 different rat
hearts were measured at each time point for each storage
solution. A total of 120 rat hearts were used to complete all
of the experiments in the study.
Measurement of myocardial biochemical function.
Myocardial biochemical function was assessed by ATP con-
tent and capacity for protein synthesis immediately after slic-
ing (0 hours) and after 2, 4, and 6 hours of storage at 4°C.
ATP content was measured with the use of a luciferin-
luciferase bioluminescent assay.7 After being weighed, the
tissue slice was placed in 1 mL of 10% trichloroacetic acid,
homogenized, and then snap frozen in liquid nitrogen and
stored at –80°C. When the collected specimens were ready
for assay, the samples were thawed and centrifuged (4200
rpm × 12 minutes). Ten microliters of the supernatant was
taken and diluted with 2 mL of HEPES buffer. Plastic tubes
were used to minimize binding of the ATP. Two hundred
microliters of each sample was pipetted into luminometer
cuvettes (Turner Designs, Sunnyvale, Calif). The luciferin-
luciferase solution was prepared to a volume of 15 mL with
30 µL of luciferase (Amgen Biologicals, Thousand Oaks,
Calif), 750 µL of luciferin (Sigma Chemical Co, St Louis,
Mo), 7.5 mL of stabilizing buffer, and 6.75 mL of HEPES
buffer. One hundred microliters of luciferin-luciferase was
added to each luminometer cuvette. As a reference, an ATP
standard was run for each set of ATP assays. ATP levels were
measured after addition of the luciferin-luciferase to each
cuvette with a luminometer (Turner Designs, Sunnyvale,
Calif), referenced to the ATP standard. So that a direct effect
of aprotinin on the ATP assay could be avoided, aprotinin at
200 KIU/mL was added to the ATP standards and the stan-
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dard curve was repeated. Similarly, the anti–TNF-α antibody
and the anti–TNF-α receptor antibody at 100 pg/mL were
separately added to the ATP standards and the standard curve
repeated. Results are expressed as nanomoles ATP per mil-
ligram wet weight.
Protein synthesis was measured by the incorporation of
radiolabeled leucine into acid precipitable proteins. After
cold storage, the slices were placed onto Teflon/titanium
rollers (Vitron, Tucson, Ariz), loaded into glass scintillation
vials, and incubated at 37°C in Waymouth solution (Gibco,
Grand Island, NY) containing [3H]leucine (Amersham, Elk
Grove, Ill). The solution was prepared with 60 µL of
[3H]leucine in 200 mL of Waymouth solution to a concentra-
tion of 0.3 µCi/mL. The slices were incubated for 4 hours in
the Vitron dynamic organ incubator. The incubated slices
were washed twice in buffer and homogenized in 1 mL of 1N
KOH. Twenty-microliter aliquots of the homogenates were
then pipetted off and 1 mL of 1.5N acetic acid was added.
The solution was left to stand for 24 hours at 4°C and then
centrifuged at 3250 rpm for 15 minutes. The resulting pellet
was washed two more times in 1 mL volumes of 1N HCl and
dissolved in 0.5 mL of 0.5N NaOH. The incorporation of
[3H]leucine into acid precipitable protein was determined by
scintillation counting a 0.5 mL aliquot of the dissolved pel-
lets after neutralization with 125 µL of 2N HCl. Results are
expressed as counts per minute of [3H]leucine incorporated
per milligram of protein.
TNF-α assay. TNF-α levels were measured with the use of
an enzyme-linked immunosorbent assay for rat TNF-α (R&D
Systems). Absorbance of samples and standards were mea-
sured with a spectrophotometer at an absorbance of 450 nm
with a microplate reader (Bio-Rad Laboratories, Hercules,
Calif). A standard curve was run with each set of assays. To
exclude a direct effect of aprotinin on the TNF-α assay, we
added aprotinin at 200 KIU/mL to the TNF-α standards and
then repeated the standard curve. Results are expressed as
picograms of TNF-α per milligram wet weight. If the addi-
tion of TNF-α to cardioplegic solution resulted in intramyo-
cardial TNF-α levels higher than those measured during cold
storage with cardioplegic solution alone, the difference was
ascribed to uptake of extracellular TNF-α into the myocardi-
um during the period of cold storage.
Nitric oxide assay. Nitric oxide levels were measured with
the use of a nitrate/nitrite colorimetric assay (Cayman
Chemical, Ann Arbor, Mich). Absorbance of samples and stan-
dards were measured with a spectrophotometer at an absorb-
ance of 540 nm with a microplate reader (Bio-Rad Lab-
oratories). A standard curve was run with each set of assays. To
exclude a direct effect of aprotinin on the nitric oxide assay, we
added aprotinin at 200 KIU/mL to the nitric oxide standards and
then repeated the standard curve. Similarly, the anti–TNF-α
antibody and the anti–TNF-α receptor antibody at 100 pg/mL
were separately added to the nitric oxide standards and the stan-
dard curve was repeated. Results are expressed as nanomolar
nitric oxide per milligrams of wet weight.
Presentation of data and statistical analysis. As the bio-
chemical assays measured levels within an individual slice at
a given time point, the data were analyzed by analysis of vari-
ance (StatView, Abacus Concepts, Berkeley, Calif) and are
expressed as mean ± standard deviation (n = 6 per group).
Both P values and F values for the statistical analysis are pre-
sented (F values appear in the figure legends).
Results
Aprotinin and preservation of myocardial bio-
chemical function. To determine whether aprotinin
preserves myocardial biochemical function during cold
storage, we measured ATP content and capacity for
protein synthesis in heart slices stored in cardioplegic
solution with aprotinin or in cardioplegic solution
alone. The presence of aprotinin had no effect on the
standard curve for ATP (data not shown), indicating
that its addition did not affect the assay. As demon-
strated in Fig 1, ATP content was higher in the slices
stored in cardioplegic solution containing aprotinin
compared with storage in cardioplegic solution alone at
each time point from zero through 6 hours (P < .0001).
To determine whether the difference in ATP content
between the two solutions at the zero-hour time point
was due to an immediate protective effect of aprotinin
or another variable, we prepared slices in cardioplegic
solution containing aprotinin and converted them to
storage in cardioplegic solution alone at the zero-hour
time point. Similarly, slices prepared in cardioplegic
solution were converted to storage in cardioplegic solu-
tion containing aprotinin at the zero-hour time point.
As demonstrated in Fig 2, the slices prepared in car-
dioplegic solution with aprotinin and stored in cardio-
plegic solution alone demonstrated a decline in ATP
content compared with those having ongoing storage in
cardioplegic solution with aprotinin (P ≤ .0001). The
slices prepared in cardioplegic solution and stored in
cardioplegic solution with aprotinin did not demon-
strate an improvement in ATP content compared with
those subjected to ongoing storage in cardioplegic
solution alone. Continuous exposure of the myocardi-
um to aprotinin immediately after cardiectomy through
the generation of the slices, then, prevented the other-
wise rapid decline in ATP stores seen with preparation
and slicing in cardioplegic solution alone. Later addi-
tion of aprotinin to cardioplegic solution at the zero-
hour time point did not significantly raise ATP content
within the myocardium.
As demonstrated in Fig 3, capacity for protein syn-
thesis, a measure of more complex biochemical func-
tion, was higher in the slices stored in cardioplegic
solution with aprotinin than in those stored in cardio-
plegic solution alone for 2, 4, and 6 hours of cold stor-
age (P < .0001).
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Aprotinin and intramyocardial generation of
TNF-α. To determine whether aprotinin inhibits the
generation of TNF-α within the myocardium during
cold storage, we measured TNF-α levels in the heart
Fig 1. Myocardial ATP content in the heart slices immediate-
ly after slicing (0 hours) and at 2, 4, and 6 hours of storage at
4°C in cardioplegic solution containing aprotinin (–◊–) or
cardioplegic solution alone (––). ATP content is higher in
the heart slices stored in cardioplegic solution containing
aprotinin than in cardioplegic solution alone for 0 (F =
149.33, P < .0001), 2 (F = 660.21, P < .0001), 4 (F = 356.12,
P < .0001), and 6 hours of cold storage (F = 124.43, P <
.0001). N = 6 slices at each time point for each solution.
Fig 2. Myocardial ATP content in the heart slices: (1) pre-
pared and stored in cardioplegic solution containing aprotinin
(–◊–); (2) prepared in cardioplegic solution containing apro-
tinin and converted to storage in cardioplegic solution alone
at the zero-hour time point (–∆–); (3) prepared in cardio-
plegic solution and converted to storage in cardioplegic solu-
tion containing aprotinin at the zero-hour time point (––);
(4) prepared and stored in cardioplegic solution alone (––).
The slices prepared in cardioplegic solution with aprotinin
and stored in cardioplegic solution alone demonstrate a
decline in ATP content compared with ongoing storage in
cardioplegic solution with aprotinin for 2 (F = 360.29, P <
.0001), 4 (F = 139.24, P < .0001), and 6 (F = 36.52, P =
.0001) hours of cold storage. The slices prepared in cardio-
plegic solution and stored in cardioplegic solution with apro-
tinin do not demonstrate an improvement in ATP content
compared with ongoing storage in cardioplegic solution
alone. N = 6 slices at each time point for each solution.
Fig 3. Capacity for protein synthesis in the heart slices imme-
diately after slicing (0 hours) and at 2, 4, and 6 hours of stor-
age at 4°C in cardioplegic solution containing aprotinin (–◊–)
or cardioplegic solution alone (––). Protein synthesis is
higher in the heart slices stored in cardioplegic solution con-
taining aprotinin compared with cardioplegic solution alone
for 2 (F = 189.62, P < .0001), 4 (F = 495.56, P < .0001), and
6 (F = 53.64, P < .0001) hours of cold storage. N = 6 slices
at each time point for each solution.
Fig 4. Intramyocardial generation of TNF-α in the heart
slices immediately after slicing (0 hours) and at 2, 4, and 6
hours of storage at 4°C in cardioplegic solution containing
aprotinin (––) or cardioplegic solution alone (––). With
storage in cardioplegic solution containing aprotinin, the
heart slices demonstrate a decrease in intramyocardial gener-
ation of TNF-α for 2 (F = 34.43, P = .0042), 4 (F = 108.27,
P = .0019), and 6 (F = 10.63, P = .0311) hours of cold stor-
age compared with storage in cardioplegic solution alone. N
= 6 slices at each time point for each solution.
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slices stored in cardioplegic solution with aprotinin or
in cardioplegic solution alone. The presence of apro-
tinin had no effect on the standard curve for TNF-α
(data not shown), indicating that its addition did not
affect the assay. With aprotinin present in cardioplegic
solution, the heart slices demonstrated a decrease in
intramyocardial generation of TNF-α for 2, 4, and 6
hours of cold storage compared with storage in cardio-
plegic solution alone (P ≤ .0311, Fig 4).
Aprotinin and uptake of TNF-α into the
myocardium. To determine whether aprotinin inhibits
the uptake of TNF-α into the myocardium, we mea-
sured TNF-α levels in the heart slices stored in cardio-
plegic solution containing TNF-α plus aprotinin or car-
dioplegic solution containing TNF-α. The addition of
TNF-α to cardioplegic solution resulted in intramy-
ocardial TNF-α levels higher than those measured dur-
ing cold storage with cardioplegic solution alone, indi-
cating that extracellular TNF-α can be taken up into the
myocardium during cold storage (Fig 5). With apro-
tinin present in cardioplegic solution containing TNF-
α, there was a decrease in the uptake of TNF-α into the
myocardium for zero through 6 hours of cold storage,
compared with storage in cardioplegic solution con-
taining TNF-α (P ≤ .002, Fig 5).
Anti–TNF-α antibodies and preservation of
myocardial biochemical function. To determine
whether TNF-α mediates the decline in myocardial
biochemical function during cold storage, we measured
ATP content and capacity for protein synthesis in heart
slices stored in cardioplegic solution containing an
anti–TNF-α antibody, an anti–TNF-α receptor anti-
body, or in cardioplegic solution alone. The presence of
an anti–TNF-α antibody or an anti–TNF-α receptor
antibody had no effect on the standard curve for ATP
(data not shown), indicating that their addition did not
affect the assay. The presence of an anti–TNF-α anti-
body or an anti–TNF-α receptor antibody in cardio-
plegic solution increased intramyocardial ATP content
for zero through 6 hours of cold storage compared with
storage in cardioplegic solution alone (P < .0001, Fig
6). Similarly, the presence of an anti–TNF-α antibody
or an anti–TNF-α receptor antibody in cardioplegic
solution increased intramyocardial protein synthesis
for 2, 4, and 6 hours of cold storage compared with stor-
age in cardioplegic solution alone (P < .0001, Fig 7).
Aprotinin and nitric oxide production. To deter-
Fig 5. Intramyocardial levels of TNF-α in the heart slices
stored in cardioplegic solution containing aprotinin (–∆–),
cardioplegic solution containing TNF-α plus aprotinin (–◊–),
cardioplegic solution containing TNF-α (––), or cardio-
plegic solution alone (––) immediately after slicing (0
hours) and at 2, 4, and 6 hours of storage at 4°C. The addition
of TNF-α to cardioplegic solution results in intramyocardial
TNF-α levels higher than those measured during cold storage
with cardioplegic solution alone, indicating that extracellular
TNF-α can be taken up into the myocardium during cold
storage. Shaded areas illustrate intramyocardial TNF-α lev-
els attributed to uptake of TNF-α. With aprotinin present in
cardioplegic solution containing TNF-α, there is a decrease
in the uptake of TNF-α into the myocardium for 0 (F = 48.22,
P < .0001), 2 (F = 17.82, P = .002), 4 (F = 73.08, P < .0001),
and 6 (F = 208.90, P < .0001) hours of cold storage, com-
pared with storage in cardioplegic solution containing TNF-
α (Fig 5).
Fig 6. Myocardial ATP content in the heart slices immediate-
ly after slicing (0 hours) and at 2, 4, and 6 hours of storage at
4°C in cardioplegic solution containing an anti–TNF-α
receptor antibody (anti–TNF-α-R1 Ab, –◊–), an anti–TNF-α
antibody (anti–TNF-α Ab, ––), or cardioplegic solution
alone (––). The presence of an anti–TNF-α antibody or an
anti–TNF-α receptor antibody in cardioplegic solution
increases myocardial ATP content for 0 (F = 339.60, P <
.0001), 2 (F = 146.20, P < 0.0001), 4 (F = 160.29, P < .0001),
and 6 (F = 101.06, P < .0001) hours of cold storage compared
with storage in cardioplegic solution alone. N = 6 slices at
each time point for each solution.
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mine whether the effects of aprotinin might be mediat-
ed through a TNF-α–induced nitric oxide–dependent
pathway, we measured nitric oxide levels in the heart
slices stored in cardioplegic solution containing apro-
tinin, an anti–TNF-α antibody, an anti–TNF-α receptor
antibody, or cardioplegic solution alone. The presence
of aprotinin, an anti–TNF-α antibody, or an anti–TNF-
α receptor antibody had no effect on the standard curve
for nitric oxide (data not shown), indicating that their
addition did not affect the assay. The addition of apro-
tinin, an anti–TNF-α antibody, or an anti–TNF-α
receptor antibody to cardioplegic solution decreased
nitric oxide levels within the myocardium for 2, 4, and
6 hours of cold storage compared with storage in car-
dioplegic solution alone (P < .0001, Fig 8).
Discussion
In these experiments, aprotinin improves preserva-
tion of myocardial ATP content and capacity for protein
synthesis during cold storage. This improvement in
myocardial biochemical function correlates with a sup-
pression in the intramyocardial generation of TNF-α
when aprotinin is present. The addition of TNF-α to
crystalloid cardioplegic solution results in intramyocar-
dial TNF-α levels higher than those measured during
cold storage with cardioplegic solution alone, indicat-
ing that extracellular TNF-α can be taken up into the
myocardium during cold storage. This uptake of TNF-
α into the myocardium is suppressed in the presence of
aprotinin. Myocardial ATP content and capacity for
protein synthesis during cold storage improved with an
anti–TNF-α antibody or an anti–TNF-α receptor anti-
body present. This implicates TNF-α as a primary
mediator of the decline in myocardial biochemical
function during cold storage in cardioplegic solution
alone. Linking these experimental results, we can con-
clude that aprotinin mediates improvement in the
preservation of myocardial biochemical function dur-
ing cold storage through the suppression of the release,
uptake, and activity of TNF-α. Finally, aprotinin sup-
presses TNF-α–induced nitric oxide production within
the myocardium during cold storage. The depression of
myocardial biochemical function by TNF-α may,
therefore, be mediated through a nitric oxide–depen-
dent pathway.
Inflammatory cytokines, in particular TNF-α, are
principal mediators of myocardial dysfunction after
ischemia-reperfusion injury.1 Both myocardial macro-
Fig 7. Capacity for protein synthesis in the heart slices imme-
diately after slicing (0 hours) and at 2, 4, and 6 hours of stor-
age at 4°C in cardioplegic solution containing an anti–TNF-
α receptor antibody (anti–TNF-α-R1 Ab, –◊–), an
anti–TNF-α antibody (anti–TNF-α Ab, ––), or cardioplegic
solution alone (––). The presence of an anti–TNF-α recep-
tor antibody in cardioplegic solution increases myocardial
protein synthesis for 2 (F = 391.10, P < .0001), 4 (F = 428.75,
P < .0001), and 6 (F = 185.49, P < .0001) hours of cold stor-
age compared with storage in cardioplegic solution alone.
The presence of an anti–TNF-α antibody in cardioplegic
solution increases myocardial protein synthesis for 2 (F =
77.34, P < .0001), 4 (F = 151.12, P < .0001), and 6 (F =
174.11, P < .0001) hours of cold storage compared with stor-
age in cardioplegic solution alone. N = 6 slices at each time
point for each solution.
Fig 8. Myocardial generation of nitric oxide in the heart
slices immediately after slicing (0 hours) and at 2, 4, and 6
hours of storage at 4°C in cardioplegic solution containing
aprotinin (–◊–), an anti–TNF-α antibody (anti-TNF-α Ab,
––), an anti–TNF-α receptor antibody (anti-TNF-α-R1 Ab,
––), or cardioplegic solution alone (––). The addition of
aprotinin, an anti–TNF-α antibody or an anti–TNF-α recep-
tor antibody to cardioplegic solution decreases nitric oxide
levels within the myocardium for 2 (F = 40.65, P < .0001), 4
(F = 102.58, P < .0001), and 6 (F = 206.45, P < .0001) hours
of cold storage compared with storage in cardioplegic solu-
tion alone. N = 6 slices at each time point for each solution.
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phages and cardiac myocytes synthesize TNF-α.1
Cardiac myocytes produce substantial amounts of
TNF-α in response to ischemia.1 In fact, the myocardi-
um can produce as much TNF-α per gram of tissue as
either the liver or the spleen.1 TNF-α produced within
the myocardium is likely the primary contributor to
myocardial dysfunction after ischemia-reperfusion.1
Locally produced TNF-α contributes to postischemic
myocardial dysfunction via direct depression of con-
tractility and induction of myocyte apoptosis.1
Mechanistically, TNF-α appears to depress systolic
function by disrupting calcium release by the sar-
coplasmic reticulum.1
Temporally, the effects of TNF-α can be divided into
early and late phases.1 The early phase occurs within
minutes of the release of TNF-α.1 This pathway is
independent of nitric oxide and is mediated by sphin-
gosine disruption of calcium transients.1 The late phase
occurs hours after release of TNF-α and is correlated
with induction of nitric oxide synthase, subsequently
resulting in release of nitric oxide, myofilament desen-
sitization to calcium, and sustained contractile dys-
function.1 Suppression of TNF-α release within the
myocardium, therefore, might modify the myocardial
dysfunction after ischemia-reperfusion injury and
improve patient outcomes.
The use of crystalloid cardioplegic solution in our
experiments eliminates the confounding variable of
macrophage production of TNF-α with blood storage.
Gurevitch and associates8 have demonstrated TNF-α
production within the myocardium during reperfusion
after arrest with crystalloid cardioplegic solution. They
concluded that TNF-α production occurs during the
reperfusion phase.8 Our results demonstrate that TNF-
α production also occurs during ischemic cold storage
before reperfusion.
Aprotinin was used at a concentration of 200
KIU/mL in all our experiments because this corre-
sponds to the concentration observed to produce anti-
inflammatory effects in vivo.9 In our studies, aprotinin
helps to maintain ATP levels during the period of
ischemic cold storage before reperfusion. This extends
the findings of Sunamori and colleagues,4 who previ-
ously demonstrated improved preservation of adenine
nucleotides with aprotinin after ischemia and reperfu-
sion. Further, the protective effects of aprotinin extend
to preservation of capacity for protein synthesis during
cold storage, indicating general preservation of cell
function beyond conservation of energy stores.
Exposure of the slices to aprotinin, an anti–TNF-α
antibody, or an anti–TNF-α receptor antibody during
the 10 minutes from cardiectomy to slice generation
resulted in an elevation in ATP levels compared with
preparation and slicing in the cardioplegic solution
alone group, as measured at the zero-hour time point.
Our crossover studies with the slices at the zero-hour
time point demonstrate that the improved ATP content
is due to an immediate protective effect conferred by
aprotinin. The further elevation in ATP levels in the
presence of an anti–TNF-α antibody or an anti–TNF-α
receptor antibody suggests more effective blockade of
TNF-α–mediated depletion of ATP stores. Mechan-
istically, the rapid depletion of ATP stores in the
absence of aprotinin and the conservation of ATP stores
over hours of cold storage when aprotinin is present
suggests that depletion of ATP stores may proceed
through both nitric oxide–dependent and nitric oxide–
independent pathways. Depletion of ATP stores occur-
ring through both nitric oxide–dependent and nitric
oxide–independent pathways would account for the
difference in ATP levels seen at the zero-hour time
point when TNF-α levels have not yet diverged.
With regard to our experimental model, the use of tis-
sue slices has advantages over both in vivo whole organ
models and in vitro cellular models to study organ
function. Advantages include a reduction in the number
of animals used, a decrease in experimental variation,
more rapid production of experimental results, and
elimination of humoral and neuronal systemic influ-
ences.10 Preservation and homogenization of tissue in a
measured, standardized fashion is much simpler with
myocardial slices rather than with whole organs, facil-
itating the measurement of quantifiable biochemical
end points. Compared with in vitro cell culture or cell
suspension models, tissue slices maintain the multicel-
lular composition of intact tissue, preserving the intra-
cellular connections used in maintaining contact inhi-
bition, signal transmission, and hormonal and ion
transport.10 These intracellular connections are typical-
ly lost with the protease digestion necessary to isolate
single cell types used with in vitro models.10 With opti-
mization of the slice thickness, efficient gas and nutri-
ent exchange can be maintained with diffusion into the
tissue of entering nutrients and oxygen and egress of
cellular by-products.10 Tissue slices, therefore, can
serve as a proxy for whole organ models.11,12
In our experience, limitations of the application of
tissue slicing to myocardial tissue include the need to
precisely maintain a slice thickness of 200 µm, as
greater slice thicknesses do not allow satisfactory dif-
fusion into the slice of oxygen and nutrients, resulting
in cell death. Similarly, myocardial slices at 37°C are
quite sensitive to changes in oxygen tension, and sig-
nificant hypoxia must be avoided to prevent cell death.
Assessment of biochemical function is a requirement
for determining effectiveness of cellular preservation
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with cold storage. Preservation of myocardial biochem-
ical function can be assessed by measurement of ATP
levels and capacity for protein synthesis. ATP stores in
the heart are critical for energy production during and
after reperfusion, as well as for prevention of structural
injury from ischemic contracture during storage.
Capacity for protein synthesis is a general indicator of
biochemical function because it requires the integration
of several complex enzymatic pathways. Maintenance
of the capacity for protein synthesis is therefore a more
sophisticated measure of the ability of the myocardium
to carry out biochemical functions integral to cell via-
bility after cold storage.
In conclusion, TNF-α depresses myocardial bio-
chemical function during cold storage through deple-
tion of ATP stores and reduction in capacity for protein
synthesis. In contradistinction, aprotinin improves
myocardial ATP levels and protein synthesis during
cold storage. Aprotinin mediates this improvement in
preservation of biochemical function through suppres-
sion of the release, uptake, and activity of TNF-α.
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Discussion
Dr Robert Robbins (Stanford, Calif). The authors have
tested the hypothesis that aprotinin mediates preservation of
myocardial biochemical function through inhibition of the
release, uptake, or activity of TNF-α. They specifically inves-
tigated the following points: whether aprotinin can preserve
myocardial biochemical function during cold storage;
whether the myocardium releases TNF-α during cold storage
before reperfusion; whether the release of TNF-α is associat-
ed with a decrease in myocardial biochemical function during
cold storage; whether aprotinin preserves myocardial bio-
chemical function during cold storage by suppression of the
release, uptake, or activity of TNF-α; and, finally, whether
aprotinin suppresses TNF-α–induced nitrous oxide produc-
tion within the myocardium. They used tissue slices of rat
myocardium for the assessment of ATP content, protein syn-
thesis, TNF-α levels, and nitric oxide levels for up to 6 hours
at 4°C. Myocardial tissue slices stored in a solution of apro-
tinin demonstrated higher ATP levels and increased capacity
for protein synthesis, a decreased level of TNF-α production
and uptake, and a decreased level of nitric oxide over time
compared with control groups not treated with aprotinin. 
I have a few comments and questions concerning these data.
You have demonstrated that aprotinin preserves ATP stores
and likewise that anti–TNF-α monoclonal antibodies to the
receptor and to TNF-α preserve ATP stores; however, these
data do not directly prove that aprotinin preserves ATP stores
through the reduction of TNF-α. Since aprotinin is a wide-
spread nonspecific inhibitor of enzymatic activity, could this
lead to some preservation of ATP stores that is independent of
TNF-α?
Dr Bull. In the manuscript we discuss in detail that ATP is
likely preserved through both nitric oxide–dependent and
nitric oxide–independent pathways.
Dr Robbins. You have highlighted some of the advantages
of using these tissue slices for this study; however, there are
obviously some important limitations to this technique, most
important, what happens during reperfusion. In an in vivo
study by Suzuki, which was referenced in your manuscript,
left ventricular function was certainly worse in isolated dog
hearts that were treated with aprotinin compared with control
hearts not treated with aprotinin. Do you have any additional
data on reperfusion data in your laboratory?
Dr Bull. No. We specifically did not look at reperfusion in
the study. I want to emphasize that our study examines
changes in the myocardium during cold storage before reper-
fusion. As you know, TNF-α is made by the myocardium pri-
marily and also by macrophages within the myocardium and
in the periphery. To control these factors, we conducted the
experiments under conditions of cold storage. To extrapolate
our data to the setting of reperfusion would require signifi-
cant additional experiments that involve a whole set of other
variables that have to be introduced and tested for, especially
macrophage production of TNF-α.
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Dr Robbins. Have you tried pretreatment of donor rats
with systemic aprotinin before cardiectomy instead of just
taking the heart out and putting it into a solution of aprotinin?
Dr Bull. No, although it is an intriguing point. The ATP
content at the zero-hour time point, which is the 10-minute
interval from the time the cardiectomy is done through the
preparation and generation of slicing, is significantly lower.
The presence of aprotinin while the hearts were being pre-
pared and sliced seems to significantly increase ATP content.
When we performed a cross-over experiment, as described in
the text, we found that when aprotinin was removed at the
zero-hour time point and instead the slices were placed in
cardioplegic solution alone, ATP content was rapidly lost.
Similarly, adding aprotinin to the slices prepared in cardio-
plegic solution at the zero-hour time point did not restore ATP
levels. Clearly, aprotinin seems to be conferring an immedi-
ate protective effect on ATP stores in the 10-minute interval
from cardiectomy through completion of the slices. This does
not hold true for protein synthesis. Protein synthesis may be
a more accurate assessment of true biochemical function
because it does require the integration of several important
enzymatic pathways. ATP as a measured biochemical func-
tion is more ephemeral and more subject to immediate
episodes of ischemia. I personally think that, of the two,
capacity for protein synthesis is the more rigorous test.
Dr Robbins. How did you do this? Are you saying that you
sectioned the heart in a solution of aprotinin?
Dr Bull. Right. 
Dr Robbins. Am I correct that at time point zero you
immediately put the heart in aprotinin?
Dr Bull. No. At the time the cardiectomy is done, the
hearts immediately go into cardioplegic solution containing
aprotinin or into one of the other study solutions. There is a
10-minute time interval from cardiectomy to the time we har-
vest the slices. 
Dr Robbins. One thing you might consider is the use of
cardioplegic solution immediately, before you start the exper-
iment, so that you stop the heart and get it cold immediately. 
The use of genetically modified TNF “knock out” animals
for these studies would be instructive since they would per-
mit the investigation of effects of aprotinin in the absence of
TNF-α. Do you have any plans to use TNF “knock outs”? I
think that would help clean up this experiment.
Dr Bull. I do not, but if you have access to them I would
love to have them.
Dr Robbins. Alternatively, you could combine aprotinin
and the anti–TNF-α antibody. Have you combined either the
receptor antibody and the antibody to TNF-α, and do you
have any data on what happens to the levels in the experi-
ments you did? I did not see any report of what happens to the
TNF-α levels with these monoclonal antibodies.
Dr Bull. We did not test specifically for that. Other groups,
especially the group at Colorado, have used monoclonal anti-
bodies to TNF-α and demonstrated salutary effects from that,
but we did not specifically test that.
Dr Robbins. Finally, on the basis of these data, have you
used aprotinin more liberally despite its cost in your clinical
cardiac practice, particularly in the high-risk cases?
Dr Bull. We have gradually increased our use of aprotinin
in our practice. We first began using it for patients requiring
complex redo operations or longer reconstructions in whom
we thought bleeding was a primary issue. As we have gained
experience in the use of aprotinin, we have focused on the
parallel pathway of suppression of inflammatory mediators.
We believe aprotinin may decrease the incidence of compli-
cations such as adult respiratory distress syndrome and pan-
creatitis through suppression of inflammatory mediators. 
Dr Edward Verrier (Seattle, Wash). I very much liked the
design of the experiment, although I do have a couple of
questions.
First, cutting slices is considerably different from having
an ischemic reperfusion model. There is no ischemia per se
because there is no lack of blood supply. You just cut the tis-
sue and put it into storage. My biggest difficulty with this
process is that protein synthesis takes time. If we get a signal
on the surface of a cell (and here we are dependent on a dif-
fusion gradient at 4°C), then we have to get a signal to the
cell. It has to go in through a signal transduction pathway, hit
a promoter, whatever the promoter is for TNF (it is probably
NF-κ-B), and turn on the gene. The gene then has to express
a messenger RNA, translate it, develop a protein, go to the
surface, and have the protein expressed. That is what I do not
understand about this model. How do you explain the fact
that you are accounting for protein synthesis over a 4-hour
period except that it happens immediately?
Dr Bull. The protein synthesis assay is done at a particular
time point after 2, 4, or 6 hours of cold storage. The slices are
removed and then incubated at 37°C to allow enzymatic activi-
ty. They are bathed in tritiated leucine to allow incorporation of
the tritiated leucine occurring at 37°C. It is not occurring at 4°C.
Dr Verrier. But once again, to get protein synthesis at 4°C,
there has to be a time frame. Maybe it is my own understand-
ing that is different here, but I think that there may be some-
thing unique to the model, and I think you are going to need
to take the next step to find out. When you take the next step,
you go into a monstrous number of variables that are going to
affect whether you really modify the response or induce actu-
al protein synthesis by such a broad agent as a TNF inhibitor.
Dr Bull. An alternative means of understanding what is
being measured is the maintenance of cell viability. In other
words, cell viability is being maintained during that period of
cold storage. Cells are lost through apoptosis or ischemia to
varying degrees in different preservation solutions. The
degree to which overall cell viability is maintained can be
assessed by measuring the degree to which capacity for pro-
tein synthesis is maintained.
Dr Verrier. That is a very intriguing concept in that a lot
of TNF is mediated through NF-κ-B. NF-κ-B goes into a
cytodestructive and a cytoprotective side. The cytoprotective
side is that you can inhibit apoptosis that is due to TNF, and
that would be very interesting to study as an extension of
this. 
